Indication

EGFR exon 18 G719X and exon 21 L861Q mutations

1 clinical trial

3 products

Clinical trial
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Status: Active (not recruiting), Estimated PCD: 2024-08-23
Product
Pemetrexed
Product
BLU-451